Jefferies has kicked off coverage of Medline Inc. with a "buy" rating, highlighting the company's impressive supply chain and private-label product model. The firm set a $50 price target, based on a detailed analysis of Medline's projected 2027 EBITDA. Medline, a major player in medical-surgical distribution, generated around $25.5 billion in revenue in 2024, split between its Medline Brand and Supply Chain Solutions segments.

The Medline Brand segment, which focuses on private-label products, posted a robust $12.5 billion in net sales with a healthy 26.1% adjusted EBITDA margin. Meanwhile, the Supply Chain Solutions segment recorded $13 billion in net sales, though with a lower 5% adjusted EBITDA margin. Medline's Prime Vendor model, a key part of its business strategy, involves hospitals committing to source most of their medical-surgical supplies through Medline.

This model has proven successful, with Medline Brand products typically increasing their share of sales over time in these partnerships. The company operates in a vast global market, estimated at $375 billion, with significant opportunities for growth. Jefferies also noted potential risks, including hospital admissions trends and competition from other distributors.

Medline's scale and strategic relationships position it well for future growth, making it an attractive investment target in the healthcare supply chain sector.